13,217 reports of this reaction
2.8% of all AMLODIPINE reports
#4 most reported adverse reaction
DYSPNOEA is the #4 most commonly reported adverse reaction for AMLODIPINE, manufactured by Azurity Pharmaceuticals, Inc.. There are 13,217 FDA adverse event reports linking AMLODIPINE to DYSPNOEA. This represents approximately 2.8% of all 472,892 adverse event reports for this drug.
Patients taking AMLODIPINE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for AMLODIPINE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for AMLODIPINE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 13,217 FDA reports for AMLODIPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.8% of all adverse event reports for AMLODIPINE, making it a notable side effect.
If you experience dyspnoea while taking AMLODIPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.